title: Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals.
abstract: OBJECTIVE
  To evaluate the effects of osthole on fatty liver, and investigate the possible mechanism.
  
  
  METHODS
  A quail model with hyperlipidemic fatty liver and rat model with alcoholic fatty liver were set up by feeding high fat diet and alcohol, respectively. These experimental animals were then treated with osthole 5-20 mg/kg for 6 wk, respectively. Whereafter, the lipid in serum and hepatic tissue, and coefficient of hepatic weight were measured.
  
  
  RESULTS
  After treatment with osthole the levels of serum total cholesterol (TC), triglyceride (TG), lower density lipoprotein-cholesterol (LDL-C), coefficient of hepatic weight, and the hepatic tissue contents of TC and TG were significantly decreased. The activity of superoxide dismutase (SOD) in liver was improved. In alcohol-induced fatty liver rats, the level of malondialdehyde (MDA) in liver was decreased. In high fat-induced fatty liver quails, glutathione peroxidase (GSH-PX) in liver was significantly improved. The histological evaluation of liver specimens demonstrated that the osthole dramatically decreased lipid accumulation.
  
  
  CONCLUSIONS
  These results suggested that osthole had therapeutic effects on both alcohol and high fat-induced fatty liver. The mechanism might be associated with its antioxidation.
authors.affiliation: Department of Pharmacology, Medical School of Soochow University, Suzhou 215123, Jiangsu Province, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Song
authors.forename: Mei-Lin
authors.initials: ML
authors.lastname: Xie
authors.forename: Lu-Jia
authors.initials: LJ
authors.lastname: Zhu
authors.forename: Ke-Ping
authors.initials: KP
authors.lastname: Zhang
authors.forename: Jie
authors.initials: J
authors.lastname: Xue
authors.forename: Zhen-Lun
authors.initials: ZL
authors.lastname: Gu
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003374:Coumarins / Q000627:therapeutic use*; D005234:Fatty Liver / Q000188:drug therapy / Q000378:metabolism; D005235:Fatty Liver, Alcoholic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005979:Glutathione Peroxidase / Q000378:metabolism; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011784:Quail; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: D000276:Adjuvants, Immunologic; D008078:Cholesterol, LDL; D003374:Coumarins; D017382:Reactive Oxygen Species; D014280:Triglycerides; D008315:Malondialdehyde; D002784:Cholesterol; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; C046627:osthol